scispace - formally typeset
Y

Yan Li

Researcher at University of Illinois at Chicago

Publications -  10
Citations -  165

Yan Li is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Estrogen & Catechol-O-methyl transferase. The author has an hindex of 8, co-authored 9 publications receiving 159 citations.

Papers
More filters
Journal ArticleDOI

Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.

TL;DR: The formation of catechols represents a minor role in cytotoxic and antiestrogenic effects in cells as compared with their phenol analogues, which implies that o-quinones formed from catechol estrogens could contribute to genotoxicity in vivo, which is ER-dependent.
Journal ArticleDOI

Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression.

TL;DR: The involvement of other genes important in cell transformation and oxidative stress are shown, strengthening the hypothesis that this mechanism plays a considerable role in 4-OHEN-induced anchorage-independent growth.
Journal ArticleDOI

Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase

TL;DR: In conclusion, inhibition of COMT methylation by 4-OHEN might reduce endogenous catechol estrogen clearance in vivo and further enhance toxicity.
Journal ArticleDOI

Inhibition of cellular enzymes by equine catechol estrogens in human breast cancer cells: specificity for glutathione S-transferase P1-1.

TL;DR: 4-OHEN caused significant decreases in GST activity in nontransformed human breast epithelial cells (MCF-10A) but not in the human hepatoma HepG2 cells, which lack GST P1-1, and other cellular enzymes including PR, PK, GR, SOD, catalase, TR, and GPX were resistant to 4-OHen-induced inhibition.
Journal ArticleDOI

Effect of halogenated substituents on the metabolism and estrogenic effects of the equine estrogen, equilenin.

TL;DR: The 4-fluoroequilenin derivatives have promise as alternatives to traditional estrogen replacement therapy due to their similar estrogenic properties with less overall toxicity.